gsk presentation, page-4

re: gsk working on ?intravenous relenza my previous post about the GSK presentation suggested that the bottleneck may be the production of the inhaler rather than production of the active ingredient, zanamivir. In that case, "a different delivery system" suggests either a different inhaler (such as a longer course "pandemic puffer" like an asthma puffer) or else an intravenous use product.

Of course, very speculative, but interesting to watch. My previous speculation on the US approving Relenza for prophylactic use was correct.

Or even it might be something as simple as packaging more medication blister packets in with the inhaler, for 20 days prophylactic use rather than 10.